NCT00203424 - Treatment of Prostate Cancer With Adjuvant Bevacizumab Plus Erlotinib | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

February 28, 2009

Study Completion Date

June 30, 2010

Conditions

Prostate Cancer

Interventions

DRUG

Erlotinib + Bevacizumab

Erlotinib every day for 24 weeks and Bevacizumab every 3 weeks for a total of 8 doses

Trial Locations (16)

Cancer Institute of Florida, P.A., Orlando

South Texas Oncology and Hematology, P.A., San Antonio

Comprehensive Cancer Centers of Nevada, Las Vegas

UCLA Medical Center, Los Angeles

Cancer Care Associates Medical Group, Inc., Redondo Beach

Pacific Shores Medical Group, Long Beach

North Valley Hematology/Oncology Medical Group, Northridge

Wilshire Oncology Medical Group, Inc., Pomona

Central Hematology Oncology Medical Group, Inc., Alhambra

San Diego Cancer Center, Vista

Virginia K. Crosson Cancer Center, Fullerton

Ventura County Hematology-Oncology Specialists, Oxnard

Sansum Santa Barbara Medical Foundation Clinic, Santa Barbara

Santa Barbara Hematology Oncology Medical Group, Inc., Santa Barbara

Comprehensive Blood and Cancer Center, Bakersfield

Central Coast Medical Oncology Corporation, Santa Maria